From: A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
Response, N (%)
Complete Response (CR)
0 (0.0)
Partial Response (PR)
Stable Disease (SD)
27 (79.4)
Progressive Disease (PD)
4 (11.8)
Not evaluable
3 (8.8)
Objective response rate (CR + PR)%
0.0
Disease control rate (CR + PR + SD)%
79.4